	Disclosure of transfers of value made by Spark during 2021 in Germany													
	EFPIA template Date of publication: 30/06/2022 For further information please go to https://www.sparktx.com/we-are-spark/corporate-social-responsibility-ethics-and-patient-safety/efpia-transparency/ or contact Sunshine@sparktx.com													
	Full Name (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered (Art. 3)	Country of Principal Practice (Schedule 1)	Principal Practice Address (Art. 3)	Unique country identifier OPTIONAL (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		contact Sunshi	TOTAL OPTIONAL	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation	Euros		
		INDIVIDUAL NAN	IED DISCLOSURE - on	e line per HCP (i.e. all transfers of value during a year for an indivi	dual HCP will be summed	d up: itemization should be a	available for the individua	al Recipient or public autho	rities' consultation only	, as appropriate)				
		l								L				
HCPs	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					N/A	N/A			7432.5		7,432.50€		
	Number of Recipients in aggregate disclosure - Art. 3.02 % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A N/A	N/A N/A			2	-			
						NA	19/25			100 %				
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
	EUROPEAN SOCIETY OF GENE & CELL THERAPY	Hannover	Germany	Carl Neuberg Str. 1			15000					15,000.00€		
HCOs	Universitätsklinikum Ulm	Ulm	Germany	Oberer Eselsberg 45/1			4000					4,000.00€		
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02													
	Number of Recipients in aggregate disclosure - Art. 3.02 % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02													
	AGGREGATE DISCLOSURE													
R &D	Transfers of Value re: Research & Development											600.00 €		

latest update: 11 December 2013 v1